[go: up one dir, main page]

MX2022009844A - Composiciones y usos del peptido similar al glucagon-1 (glp-1). - Google Patents

Composiciones y usos del peptido similar al glucagon-1 (glp-1).

Info

Publication number
MX2022009844A
MX2022009844A MX2022009844A MX2022009844A MX2022009844A MX 2022009844 A MX2022009844 A MX 2022009844A MX 2022009844 A MX2022009844 A MX 2022009844A MX 2022009844 A MX2022009844 A MX 2022009844A MX 2022009844 A MX2022009844 A MX 2022009844A
Authority
MX
Mexico
Prior art keywords
compositions
glp
kits
phenol
preparation
Prior art date
Application number
MX2022009844A
Other languages
English (en)
Inventor
Dorthe Kot Engelund
Søren Snitker
Andrew Mark Louw
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74668840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022009844(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2022009844A publication Critical patent/MX2022009844A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a las composiciones farmacéuticas del péptido GLP-1 semaglutida que comprende no más de 0.1 % (p/p) de fenol y más de 6.4 mg/ml de cloruro de sodio, su preparación, kits que comprenden las composiciones, así como también sus usos.
MX2022009844A 2020-02-18 2021-02-17 Composiciones y usos del peptido similar al glucagon-1 (glp-1). MX2022009844A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP20157963 2020-02-18
EP20171240 2020-04-24
EP20180645 2020-06-17
EP20180832 2020-06-18
EP21150056 2021-01-04
EP21151004 2021-01-11
EP21154657 2021-02-02
PCT/EP2021/053809 WO2021144477A1 (en) 2020-02-18 2021-02-17 Glp-1 compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2022009844A true MX2022009844A (es) 2022-09-05

Family

ID=74668840

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022009844A MX2022009844A (es) 2020-02-18 2021-02-17 Composiciones y usos del peptido similar al glucagon-1 (glp-1).
MX2022009523A MX2022009523A (es) 2020-02-18 2021-02-17 Formulaciones farmaceuticas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022009523A MX2022009523A (es) 2020-02-18 2021-02-17 Formulaciones farmaceuticas.

Country Status (15)

Country Link
US (4) US11318191B2 (es)
EP (3) EP4106727A1 (es)
JP (3) JP2023512910A (es)
KR (2) KR20220143037A (es)
CN (2) CN115135305A (es)
AU (2) AU2021208601B2 (es)
BR (2) BR112022013795A2 (es)
CA (2) CA3165359A1 (es)
CL (1) CL2022002084A1 (es)
CO (2) CO2022010915A2 (es)
IL (2) IL294521A (es)
MX (2) MX2022009844A (es)
PE (2) PE20221575A1 (es)
TW (2) TW202140063A (es)
WO (2) WO2021144476A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46990B1 (fr) 2017-08-24 2024-03-29 Novo Nordisk As Compositions glp-1 et ses utilisations
JP2023512910A (ja) * 2020-02-18 2023-03-30 ノヴォ ノルディスク アー／エス 医薬製剤
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
JP2024544920A (ja) 2021-11-10 2024-12-05 アイ２オー セラピューティクス，インク． イオン液体組成物
CN114249808B (zh) * 2021-12-27 2024-11-12 江苏诺泰澳赛诺生物制药股份有限公司 一种Cagrilintide的合成方法
CN114660214B (zh) * 2022-02-18 2024-04-05 兰州积石药业有限公司 一种司美格鲁肽的液相色谱检测方法及其应用
CN118976010A (zh) * 2022-12-05 2024-11-19 齐鲁制药有限公司 一种司美格鲁肽吸入喷雾剂及其制备方法
CN116159027A (zh) * 2022-12-29 2023-05-26 江苏诺泰澳赛诺生物制药股份有限公司 一种司美格鲁肽冻干药物组合物及其制备方法
WO2024148155A1 (en) 2023-01-06 2024-07-11 Nano Precision Medical, Inc. Formulations, devices and methods for a glp-1 agonist
KR102792621B1 (ko) * 2023-06-02 2025-04-08 주식회사 지투지바이오 카그릴린타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방성 미립구 제제 및 이의 제조방법
WO2024256632A1 (en) * 2023-06-15 2024-12-19 Novo Nordisk A/S Pharmaceutical formulations of an amylin receptor agonist and a glp-1 receptor agonist comprising a cyclodextrin

Family Cites Families (462)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2444570A (en) 1948-07-06 Drive for counter numeral wheels
GB735443A (en) 1952-09-02 1955-08-24 English Numbering Machines Improvements in or relating to counting devices
US2828742A (en) 1957-05-02 1958-04-01 American Home Prod Cartridge-needle unit
NL121491C (es) 1963-05-02
US3318289A (en) 1965-05-11 1967-05-09 Northern Ind Products Bi-stable mechanism
CH499734A (de) 1968-07-19 1970-11-30 Kienzle Apparate Gmbh Klinkengesperre als Einrichtungs- und Überholkupplung
US3758683A (en) 1971-04-30 1973-09-11 R Jackson Insulin product
US4282316A (en) 1979-09-11 1981-08-04 Modrovich Ivan Endre Stabilized enzymic solutions for determining urea
PT72703B (en) 1980-03-21 1982-11-15 Wellcome Found Stabilised ophtalmic formulation
US4425346A (en) 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
IE52621B1 (en) 1981-02-12 1988-01-06 Turner Robert Charles Dose metering plunger devices for use with syringes
US4568335A (en) 1981-08-28 1986-02-04 Markwell Medical Institute, Inc. Device for the controlled infusion of medications
US4394863A (en) 1981-10-23 1983-07-26 Survival Technology, Inc. Automatic injector with cartridge having separate sequentially injectable medicaments
DE3204178C2 (de) 1982-02-06 1986-03-20 Eppendorf Gerätebau Netheler + Hinz GmbH, 2000 Hamburg Pipettiervorrichtung
US4483849A (en) 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
US4498788A (en) 1983-06-03 1985-02-12 Diehl Gmbh & Co. Escapement for a timer
DE3468173D1 (en) 1983-09-07 1988-02-04 Disetronic Ag Portable infusion apparatus
US4468346A (en) 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
JPS60129941U (ja) 1984-02-09 1985-08-31 テルモ株式会社 医療用器具
US4592745A (en) 1984-02-29 1986-06-03 Novo Industri A/S Dispenser
FR2583291A1 (fr) 1985-06-14 1986-12-19 Hazon Bernard Dispositif d'avancement pas a pas du piston de seringues par double vis coaxiale avec controle du debit d'injection. application aux injections medicamenteuses intra-dermiques repetitives
DE3546150A1 (de) 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
AU6541986A (en) 1985-11-08 1987-06-02 Disetronic A.G. Injection instrument
DE3609555A1 (de) 1986-03-21 1987-09-24 Josef Porner Blutentnahmespritze
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
CA1341320C (en) 1986-05-05 2001-11-20 Joel Habener Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4917685A (en) 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
DE3638984C3 (de) 1986-11-14 1993-11-18 Haselmeier Wilhelm Fa Injektionsgerät
US5716990A (en) 1987-03-09 1998-02-10 Cancer Research Campaign Technology Limited Drug delivery systems
DK177187A (da) 1987-04-07 1988-10-08 Dcp Af 1988 As Doseringsenhed til dosering af et antal afmaalte maengder af en vaeske, saasom insulin, fra en glasampul
DE3715258C2 (de) 1987-05-08 1996-10-31 Haselmeier Wilhelm Fa Injektionsgerät
JP2818176B2 (ja) 1987-05-14 1998-10-30 コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガナイゼーション ホエー蛋白フラクション
GB8713810D0 (en) 1987-06-12 1987-07-15 Hypoguard Uk Ltd Measured dose dispensing device
FI883338A7 (fi) 1987-07-16 1989-01-17 Bristol Myers Squibb Co Doksorubisiinihydrokloridin vesiliuoksia
IT1222331B (it) 1987-08-25 1990-09-05 Bruno Micovilovich Siringa di sicurezza per usi parentali,a disimpegno autonomo e rapido dell'ago dopo l'uso
US4919596A (en) 1987-12-04 1990-04-24 Pacesetter Infusion, Ltd. Fluid delivery control and monitoring apparatus for a medication infusion system
US4833379A (en) 1988-01-13 1989-05-23 Sherwood Medical Company Motor control fail-safe circuit
CH675078A5 (es) 1988-01-22 1990-08-31 Nosta Ag
DE3900926C2 (de) 1988-02-08 1999-05-12 Disetronic Licensing Ag Spritzenförmiges Injektionsgerät und Injektionsgerätebaukasten
US4973318A (en) 1988-02-10 1990-11-27 D.C.P. Af 1988 A/S Disposable syringe
DK166948B1 (da) 1988-02-10 1993-08-09 Dcp Af 1988 As Doseringsenhed til dosering af et antal afmaalte maengder af en vaeske, saasom insulin, fra en glastubule
WO1990000200A1 (en) 1988-06-27 1990-01-11 Genex Corporation Thermal release of recombinant protein into culture media
EP0359070B1 (de) 1988-09-12 1995-01-11 Grässlin Kg Richtgesperre für eine Schaltuhr
GB8900763D0 (en) 1989-01-13 1989-03-08 Kabi Vitrum Peptide Hormones A Multi-dose syringe
US5216437A (en) 1989-02-02 1993-06-01 Canon Kabushiki Kaisha Ink, and recording method making use of same
DK68789A (da) 1989-02-14 1990-08-15 Novo Nordisk As Injektionspen
HU203372B (en) 1989-02-24 1991-07-29 Richter Gedeon Vegyeszet Process for producing hyaluronic associates and pharmaceutical compositions and cosmetics comprising such active ingredient
JPH04504246A (ja) 1989-03-20 1992-07-30 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン刺激ホルモン
JP2822447B2 (ja) 1989-05-19 1998-11-11 住友電気工業株式会社 酸化物超電導線材の製造方法および装置
US4994033A (en) 1989-05-25 1991-02-19 Schneider (Usa) Inc. Intravascular drug delivery dilatation catheter
US5226895A (en) 1989-06-05 1993-07-13 Eli Lilly And Company Multiple dose injection pen
DE3927286C2 (de) 1989-08-18 1997-07-24 Roehm Gmbh Wäßrige Enzym-Flüssigformulierungen
US5216011A (en) 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
EP0431679B1 (en) 1989-12-05 1994-10-19 Merck & Co. Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from yeast
DK17890A (da) 1990-01-22 1991-07-23 Novo Nordisk As Fremgangsmaade og apparat til opblanding og injicering af et laegemiddel
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
JP3262329B2 (ja) 1990-01-24 2002-03-04 アイ． バックレイ，ダグラス 糖尿病治療に有用なｇｌｐ―１アナログ
DE4002066A1 (de) 1990-01-25 1991-08-01 Basf Ag Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen
GB9007113D0 (en) 1990-03-29 1990-05-30 Sams Bernard Dispensing device
US5207752A (en) 1990-03-30 1993-05-04 Alza Corporation Iontophoretic drug delivery system with two-stage delivery profile
US5318540A (en) 1990-04-02 1994-06-07 Pharmetrix Corporation Controlled release infusion device
US5492534A (en) 1990-04-02 1996-02-20 Pharmetrix Corporation Controlled release portable pump
US5226896A (en) 1990-04-04 1993-07-13 Eli Lilly And Company Dose indicating injection pen
IT220491Z2 (it) 1990-04-13 1993-09-24 Stilolinea Srl Penna a sfera del tipo a punta scrivente rientrante
DE69129110T2 (de) 1990-05-10 1998-12-10 Bechgaard International Research And Development A/S, Hellerup Pharmazeutische zubereitung enthaltend n-glykofurole und n-äthylenglykole
US5257987A (en) 1990-05-21 1993-11-02 Pharmetrix Corporation Controlled release osmotic infusion system
ATE123418T1 (de) 1990-09-21 1995-06-15 Novo Nordisk As Adaptor.
US5284480A (en) 1990-11-09 1994-02-08 Medtronic, Inc. Inflation/deflation syringe with threaded plunger
GB9026191D0 (en) 1990-12-01 1991-01-16 Harris Pharma Ltd Breath actuated dispensing device
US5331954A (en) 1990-12-21 1994-07-26 Novo Nordisk A/S Device for nasal delivery of liquid medications
US5232706A (en) 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
AU641206B2 (en) 1991-01-22 1993-09-16 Eli Lilly And Company Multiple dose injection pen
DE69203472T2 (de) 1991-02-07 1996-01-04 Terumo Corp Dosiereinrichtung für Injektor.
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
WO1992017571A1 (en) 1991-03-27 1992-10-15 Novo Nordisk A/S Catalase, its production and use
US5258377A (en) 1991-04-08 1993-11-02 Taiho Pharmaceutical Co., Ltd. 2-spirocyclopropyl 4-acylcephems
DE4112259A1 (de) 1991-04-15 1992-10-22 Medico Dev Investment Co Injektionsgeraet
DK68991D0 (da) 1991-04-17 1991-04-17 Novo Nordisk As Manifold
US5645052A (en) 1991-04-26 1997-07-08 The Boc Group Plc Anaesthetic vaporizer with expandable/contractable reservoir for pumping liquid anaesthetic
SE9101381D0 (sv) 1991-05-07 1991-05-07 Tomas Moks Peptide hormone solution
DE59202070D1 (de) 1991-07-24 1995-06-08 Medico Dev Investment Co Injektor.
DK175491D0 (da) 1991-10-18 1991-10-18 Novo Nordisk As Apparat
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
DK194291D0 (da) 1991-11-29 1991-11-29 Novo Nordisk As Sproejte til automatisk injektion.
AU3156493A (en) 1991-11-29 1993-06-28 Novo Nordisk A/S A pen-shaped syringe
US5246417A (en) 1991-12-11 1993-09-21 Alza Corporation Indicator for iontophoresis system
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
FR2686460B1 (fr) 1992-01-20 1994-03-11 Labinal Precision Mecanique Organe de contact electrique femelle.
US5279585A (en) 1992-02-04 1994-01-18 Becton, Dickinson And Company Medication delivery pen having improved dose delivery features
CH682968B5 (fr) 1992-02-12 1994-06-30 Rolex Montres Procédé de fabrication d'un joint et joint pour dispositif de commande étanche pour montre obtenu selon ce procédé.
CH682806A5 (de) 1992-02-21 1993-11-30 Medimpex Ets Injektionsgerät.
DE4208677A1 (de) 1992-03-18 1993-09-23 Injecta Gmbh Steinach Injektionsvorrichtung, insbesondere fuer sehgeschaedigte diabetiker
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5546932A (en) 1992-03-25 1996-08-20 Tebro Sa Powder jet dispenser for medicament inhalation therapies
US5271527A (en) 1992-04-02 1993-12-21 Habley Medical Technology Corporation Reusable pharmaceutical dispenser with full stroke indicator
US5281198A (en) 1992-05-04 1994-01-25 Habley Medical Technology Corporation Pharmaceutical component-mixing delivery assembly
JP3631490B2 (ja) 1992-05-13 2005-03-23 ノバルティス ファーマ株式会社 シクロスポリン含有眼科用組成物
AU671117B2 (en) 1992-06-15 1996-08-15 Scios Inc. Glucagon-like peptide and insulinotropin derivatives
UA26190C2 (uk) 1992-07-28 1999-07-19 Сейфтек Ай Лімітед Шприц
GB9219849D0 (en) 1992-09-19 1992-10-28 Hypoguard Uk Ltd Device
DE69329774T2 (de) 1992-10-15 2001-06-21 Baxter International Inc., Deerfield Infusionspumpe mit elektronisch ladbarer medikamentenbibliothek
US5545147A (en) 1992-10-20 1996-08-13 Eli Lilly And Company Anti-backup improvement for hypodermic syringes
US5378233A (en) 1992-11-18 1995-01-03 Habley Medical Technology Corporation Selected dose pharmaceutical dispenser
US5320609A (en) 1992-12-07 1994-06-14 Habley Medical Technology Corporation Automatic pharmaceutical dispensing syringe
GB9226423D0 (en) 1992-12-18 1993-02-10 Sams Bernard Incrementing mechanisms
NZ287126A (en) 1993-02-19 1997-10-24 Medicorp Holding Prefilled syringe comprises a stopper-piston-valve with a pre-cut slot compressed laterally to seal the slot in storage phase
US5383865A (en) 1993-03-15 1995-01-24 Eli Lilly And Company Medication dispensing device
US5584815A (en) 1993-04-02 1996-12-17 Eli Lilly And Company Multi-cartridge medication injection device
ZA941881B (en) 1993-04-02 1995-09-18 Lilly Co Eli Manifold medication injection apparatus and method
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
SE9301494D0 (sv) 1993-04-30 1993-04-30 Kabi Pharmacia Ab A device for dosing liquid preparation
DK52393D0 (es) 1993-05-05 1993-05-05 Novo Nordisk As
AU7531094A (en) 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
CA2171424C (en) 1993-09-17 2002-06-04 Svend Havelund Acylated insulin
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
ATE188611T1 (de) 1993-11-19 2000-01-15 Searle & Co Transdermale zusammensetzung von n-(n-(5-(4- (aminoiminomethyl)phenyl-1-oxopentyl)-l-alpha- aspartyl)-l-phenylalanin oder deren esterderivaten und ihre pharmazeutischverwendbaren salze
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5478316A (en) 1994-02-02 1995-12-26 Becton, Dickinson And Company Automatic self-injection device
US5514097A (en) 1994-02-14 1996-05-07 Genentech, Inc. Self administered injection pen apparatus and method
US5562623A (en) 1994-02-14 1996-10-08 Univec Single-use syringe assembly including spring clip lock and plunger
WO1995022560A1 (en) 1994-02-22 1995-08-24 The Syntex-Synergen Neuroscience Joint Venture Pharmaceutical formulations of cntf
WO1995029996A1 (en) 1994-05-03 1995-11-09 Novo Nordisk A/S Alkaline glucose oxidase
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5750140A (en) 1994-05-20 1998-05-12 Novo Nordisk A/S Transdermal delivery of tiagabine
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
CA2197671A1 (en) 1994-06-15 1995-12-21 Hubert Menendez Locking device for syringe or like instrument
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5725508A (en) 1994-06-22 1998-03-10 Becton Dickinson And Company Quick connect medication delivery pen
US5827232A (en) 1994-06-22 1998-10-27 Becton Dickinson And Company Quick connect medication delivery pen
US5440976A (en) 1994-08-23 1995-08-15 Fred Giuliano Adjustable dispensing stirrer for soluble sweeteners
WO1996005878A1 (fr) 1994-08-24 1996-02-29 Eli Lilly Japan Kabushiki Kaisha Appareil pour injections
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5549574A (en) 1994-08-30 1996-08-27 Eli Lilly And Company Cartridge assembly for use in a pen-type medicament injector
CA2157219C (en) 1994-08-31 2010-10-05 Munehiro Noda Process for purifying recombinant human serum albumin
KR970705343A (ko) 1994-09-09 1997-10-09 안네 제케르 콘택트 렌즈의 세척, 살균 및 보존(cleaning, disinfecting and preserving contact lenses)
US5549575A (en) 1994-09-13 1996-08-27 Becton Dickinson And Company Cartridge retainer assembly for medication delivery pen
US5582598A (en) 1994-09-19 1996-12-10 Becton Dickinson And Company Medication delivery pen with variable increment dose scale
DE69501406T2 (de) 1994-09-20 1998-05-20 Novonordisk As Verfahren zur behandlung einer wässrigen proteinlösung, um darin enthaltene mikroorganismen zu töten, ohne koagulation zu verursachen
ZA958073B (en) 1994-09-28 1996-04-23 Anthony William Manicom Method of and apparatus for administering a drug to a patient
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
AU4298596A (en) 1994-12-23 1996-07-19 Novo Nordisk A/S Protracted glp-1 compositions
BR9607013B1 (pt) 1995-02-03 2011-03-09 processo de construção de uma variante de uma alfa-amilase de bacillus original derivada de uma cepa de b. licheniformis, de b. amyloliquefaciens, de b. stearothermophilus ou de um bacillus sp. alcalofìlico.
WO1996024369A1 (en) 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
GB9503969D0 (en) 1995-02-28 1995-04-19 Sams Bernard Incrementing mechanism
WO1996027400A1 (en) 1995-03-07 1996-09-12 Eli Lilly And Company Recyclable medication dispensing device
ATE245659T1 (de) 1995-03-17 2003-08-15 Novo Nordisk As Insulinabkömmlinge
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
JPH11511118A (ja) 1995-06-02 1999-09-28 ノボ ノルディスク アクティーゼルスカブ タンパク質溶液のＡ１／Ｆｅ処理とその後の膜濃縮
PL181217B1 (pl) 1995-06-02 2001-06-29 Novo Nordisk As Strzykawka
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
CN1103810C (zh) 1995-06-13 2003-03-26 诺沃奇梅兹有限公司 含苯基硼酸衍生物酶稳定剂的液冻组合物
US5688251A (en) 1995-09-19 1997-11-18 Becton Dickinson And Company Cartridge loading and priming mechanism for a pen injector
US5674204A (en) 1995-09-19 1997-10-07 Becton Dickinson And Company Medication delivery pen cap actuated dose delivery clutch
JP3060287B2 (ja) 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
US5899879A (en) 1995-12-19 1999-05-04 Genesis Medical Technologies, Inc. Spring-actuated needleless injector
CA2246731C (en) 1996-02-23 2006-01-03 Novo Nordisk A/S Syringe with electronic representation of parameters
US6440460B1 (en) 1996-03-05 2002-08-27 Allergan Sales, Inc. Pharmaceutical compositions containing buffered ortho ester polymers
UA35653C2 (uk) 1996-03-12 2001-04-16 Ново Нордіск А/С Пристрій для ін'єкцій
ATE221396T1 (de) 1996-04-02 2002-08-15 Disetronic Licensing Ag Injektionsgerät
EP0895481B1 (en) 1996-04-24 2000-09-06 Novo Nordisk A/S Injection needle
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
ATE241997T1 (de) 1996-07-03 2003-06-15 Alza Corp Nicht-waessrige protische peptidzubereitungen
UA42109C2 (uk) 1996-07-05 2001-10-15 Ново Нордіск А/С Гнучкий шток поршня
EP0910418B1 (en) 1996-07-05 2003-09-10 Novo Nordisk A/S Automatic needle insertion mechanism
PL330817A1 (en) 1996-07-05 1999-06-07 Novo Nordisk As Dose establishing device
US5981489A (en) 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
US5962407A (en) 1996-07-26 1999-10-05 Kelly; Michael T. Loloatin derivatives and analogs
EP0966297B2 (en) 1996-08-08 2013-02-27 Amylin Pharmaceuticals, Inc. Regulation of gastrointestinal motility
JPH10101696A (ja) 1996-08-08 1998-04-21 Shinotesuto:Kk 形質転換体にて発現される蛋白質に含まれる夾雑物質の除去方法及び精製蛋白質
US5709662A (en) 1996-08-23 1998-01-20 Becton Dickinson France, S.A. Cartridge for an injection device
US5843036A (en) 1996-08-23 1998-12-01 Becton Dickinson And Company Non-dosing cartridge for an injection device
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
CZ300837B6 (cs) 1996-08-30 2009-08-26 Novo Nordisk A/S Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití
US6379339B1 (en) 1996-09-13 2002-04-30 Nova Nordisk A/S Syringe
US5947934A (en) 1996-09-13 1999-09-07 Novo Nordisk A/S Dose display for an injection syringe
US6110149A (en) 1996-09-13 2000-08-29 Novo Nordisk A/S Syringe
PL185804B1 (pl) 1996-09-13 2003-08-29 Novo Nordisk As Urządzenie iniekcyjne w postaci strzykawkiUrządzenie iniekcyjne w postaci strzykawki
EP0927055B1 (en) 1996-09-20 2001-12-05 Novo Nordisk A/S Working cylinder
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
TW524667B (en) 1996-12-05 2003-03-21 Pfizer Parasiticidal pyrazoles
US5954689A (en) 1996-12-20 1999-09-21 Novo Nordisk A/S Jet injector
EP1629849B2 (en) 1997-01-07 2017-10-04 Amylin Pharmaceuticals, LLC Pharmaceutical compositions comprising exendins and agonists thereof
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
NZ336793A (en) 1997-01-20 2000-08-25 Japan Energy Corp Method for stabilizing peptides by adding an organic acid and then lyophilizing the peptide mixture
GB2321419B (en) 1997-01-27 2001-02-07 Medic Aid Ltd Atomizer
JP2001511033A (ja) 1997-02-04 2001-08-07 ノボ ノルディスク アクティーゼルスカブ 液状薬剤懸濁液の投与装置
DE29703820U1 (de) 1997-03-03 1998-07-02 Medico Development Investment Co., Ascona Injektionsgerät
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6277097B1 (en) 1997-03-25 2001-08-21 Novo Nordisk A/S Injection system
AU6586298A (en) 1997-03-31 1998-10-22 Eli Lilly And Company Glucagon-like peptide-1 analogs
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
RU2111019C1 (ru) 1997-05-22 1998-05-20 Сергей Александрович Хворостов Универсальный инъектор
IL132884A0 (en) 1997-05-23 2001-03-19 Sikiric Predrag Body protection compound peptide salts with organo-protective activity pharmaceutical and diagnostic compositions containing the same the use thereof and process for preparing the same
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO1998056381A1 (en) 1997-06-09 1998-12-17 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
US6074372A (en) 1997-06-09 2000-06-13 Novo Nordisk A/S Dose setting mechanism and an injection syringe having such a dose setting mechanism
US6003736A (en) 1997-06-09 1999-12-21 Novo Nordisk A/S Device for controlled dispensing of a dose of a liquid contained in a cartridge
PE79099A1 (es) 1997-06-13 1999-08-24 Lilly Co Eli Formulaciones de insulina estables
US6796970B1 (en) 1997-06-17 2004-09-28 Novo Nordisk A/S Dose setting device
US5961496A (en) 1997-06-17 1999-10-05 Novo Nordisk A/S Syringe with tiltable nut for quick piston disengagement
JP3503129B2 (ja) 1997-06-30 2004-03-02 荒川化学工業株式会社 カラーフィルタ層用剥離剤およびカラーフィルタ用ガラス基板の再生方法
WO1999002210A1 (en) 1997-07-11 1999-01-21 Novo Nordisk A/S An apparatus for the registration of the setting of a medical device
EP0996476B1 (en) 1997-07-14 2003-05-21 Novo Nordisk A/S Cylinder ampoule
EP0996477B1 (en) 1997-07-14 2004-01-14 Novo Nordisk A/S Injection member
DE19730999C1 (de) 1997-07-18 1998-12-10 Disetronic Licensing Ag Dosierknopfsicherung an einer Vorrichtung zur dosierten Verabreichung eines injizierbaren Produkts
US5921966A (en) 1997-08-11 1999-07-13 Becton Dickinson And Company Medication delivery pen having an improved clutch assembly
FR2767479B1 (fr) 1997-08-22 1999-10-22 Aguettant Lab Dispositif d'injection de medicament
WO1999016485A1 (en) 1997-09-29 1999-04-08 Becton Dickinson And Company Injection device and drug cartridge for preventing cross-use of the device and drug cartridge
EP2042161A1 (en) 1997-10-01 2009-04-01 Novadel Pharma Inc. Propellant-free spray composition comprising anti-emetic agent
JP2003525846A (ja) 1997-10-24 2003-09-02 ノボ ノルディスク アクティーゼルスカブ ヒトインスリン誘導体の集合体
JP4239131B2 (ja) 1997-10-24 2009-03-18 ジェネンテック・インコーポレーテッド 分子の精製
US6312413B1 (en) 1997-10-30 2001-11-06 Novo Nordisk A/S Cylinder ampoule
WO1999029336A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
DE29721752U1 (de) 1997-12-09 1998-02-12 Siemens AG, 80333 München Crimpkontakt für Stecksysteme
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
JPH11249087A (ja) 1997-12-18 1999-09-17 Tome:Kk コンタクトレンズ用液剤
CA2365742C (en) 1998-01-09 2013-04-30 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
WO1999034764A2 (en) 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
ATE375393T1 (de) 1998-01-30 2007-10-15 Asubio Pharma Co Ltd Verfahren zur herstellung eines peptids mittels eines hilfspeptids
HU222513B1 (hu) 1998-01-30 2003-08-28 Novo Nordisk A/S Injekciós fecskendő
DE69943039D1 (de) 1998-02-13 2011-01-27 Amylin Pharmaceuticals Inc Neue verbindungen mit gemischter amylin aktivität
CA2320371C (en) 1998-02-13 2012-01-17 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
KR100637433B1 (ko) 2004-05-24 2006-10-20 삼성에스디아이 주식회사 발광 표시 장치
ES2265181T3 (es) 1998-02-13 2007-02-01 Bioniche Life Sciences Inc. Sistema de administracion de farmacos.
US6221053B1 (en) 1998-02-20 2001-04-24 Becton, Dickinson And Company Multi-featured medication delivery pen
US6096010A (en) 1998-02-20 2000-08-01 Becton, Dickinson And Company Repeat-dose medication delivery pen
US6248095B1 (en) 1998-02-23 2001-06-19 Becton, Dickinson And Company Low-cost medication delivery pen
AU2610599A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
JP2002504518A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO1999047160A1 (en) 1998-03-13 1999-09-23 Novo Nordisk A/S Stabilized aqueous peptide solutions
ATE269103T1 (de) 1998-03-13 2004-07-15 Novo Nordisk As Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
WO1999057566A1 (en) 1998-05-01 1999-11-11 The University Of Tennessee Research Corporation Flow cytometric characterization of amyloid fibrils
EP1085880A2 (en) 1998-06-11 2001-03-28 Cerus Corporation Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells
EP1094857B1 (en) 1998-07-08 2003-10-08 Novo Nordisk A/S A medical delivery device and a cartridge assembly for use in the same
AU765584B2 (en) 1998-09-17 2003-09-25 Eli Lilly And Company Protein formulations
US6033376A (en) 1998-09-30 2000-03-07 Allergan Sales, Inc. Wound shaper sleeve
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
US6605067B1 (en) 1998-11-20 2003-08-12 Novo Nordisk A/S Injection needle
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
CA2358107C (en) 1998-12-22 2011-08-23 Eli Lilly And Company Shelf-stable formulation of glucagon-like peptide-1
WO2000041546A2 (en) 1999-01-14 2000-07-20 Amylin Pharmaceuticals, Inc. Novel exendin agonist formulations and methods of administration thereof
DE29900482U1 (de) 1999-01-14 2000-08-31 Medico Development Investment Co., Ascona Injektionsgerät
EP1071517B1 (de) 1999-02-14 2008-04-02 Ing. Erich Pfeiffer GmbH Spender für fliessfähige medien
US6258062B1 (en) 1999-02-25 2001-07-10 Joseph M. Thielen Enclosed container power supply for a needleless injector
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
EP1956000B1 (en) 1999-03-17 2016-10-05 Novo Nordisk A/S Acylating agents useful for acylating peptides
SE9901366D0 (sv) 1999-04-16 1999-04-16 Pharmacia & Upjohn Ab Injector device and method for its operation
FR2793684B1 (fr) 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
AU5750600A (en) 1999-06-17 2001-01-22 Regents Of The University Of California, The Continuous cardiac perfusion preservation with peg-hb for improved hypothermic storage
ES2291210T3 (es) 1999-06-21 2008-03-01 Eli Lilly And Company Uso sinergistico de tiazolidindionas con peptido-1 tipo glucagona y sus agonistas para tratar la diabetes no insulina-dependiente.
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
ES2258469T3 (es) 1999-08-05 2006-09-01 Becton Dickinson And Company Lapiz de administracion de medicacion.
TW453884B (en) 1999-09-16 2001-09-11 Novo Nordisk As Dose setting limiter
ATE309820T1 (de) 1999-09-20 2005-12-15 Lilly Co Eli Verwendung einer parathyroidhormone zur reduktion des krebsrisikos
US6514230B1 (en) 1999-10-12 2003-02-04 Novo Nordisk A/S Air shot mechanism for electronic injection devices
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
DE60018105T2 (de) 1999-12-16 2005-12-29 Eli Lilly And Co., Indianapolis Polypeptidzusammensetzungen mit verbesserter stabilität
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
EP1250126A2 (en) 2000-01-11 2002-10-23 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
EP1396499A3 (en) 2000-01-27 2004-12-29 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (GLP-1) compounds
MXPA02007231A (es) 2000-01-27 2002-12-09 Lilly Co Eli Proceso para solubilizar los compuestos de peptido 1 similares a glucagon.
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
GB0007071D0 (en) 2000-03-24 2000-05-17 Sams Bernard One-way clutch mechanisms and injector devices
WO2001077141A1 (en) 2000-04-06 2001-10-18 Novo Nordisk A/S Shock heat treatment of polypeptides
US6692472B2 (en) 2000-05-04 2004-02-17 Novo Nordisk A/S Injection device, a preassembled dose setting and injection mechanism for an injection device, and a method of assembling an injection device
WO2001087322A2 (en) 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
US6547763B2 (en) 2000-05-18 2003-04-15 Novo Nordisk A/S Dose display for injection device
US6716198B2 (en) 2000-05-18 2004-04-06 Novo Nordisk A/S Injection device
US6547764B2 (en) 2000-05-31 2003-04-15 Novo Nordisk A/S Double pointed injection needle
DK1294757T3 (da) 2000-06-16 2007-03-19 Lilly Co Eli Glucagonlignende peptid 1-analoger
US6663602B2 (en) 2000-06-16 2003-12-16 Novo Nordisk A/S Injection device
JP2004503337A (ja) 2000-07-14 2004-02-05 ノボ　ノルディスク　アクティーゼルスカブ 液体薬物射出装置及び所望の投与量を射出させる方法
WO2002024257A1 (en) 2000-09-22 2002-03-28 Novo Nordisk A/S A medication delivery device
JP4798833B2 (ja) 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 加熱処理工程を含むヒト血清アルブミンの製造方法
AU2689702A (en) 2000-12-07 2002-06-18 Lilly Co Eli Glp-1 fusion proteins
EP1351984A2 (en) 2000-12-13 2003-10-15 Eli Lilly And Company Amidated glucagon-like peptide-1
CN1501809B (zh) 2000-12-13 2012-10-10 伊莱利利公司 应用胰高血糖素样促胰岛肽的长期治疗方案
US20020151467A1 (en) 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
US6899699B2 (en) 2001-01-05 2005-05-31 Novo Nordisk A/S Automatic injection device with reset feature
GB2371227A (en) 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
JP4278382B2 (ja) 2001-02-14 2009-06-10 ノボ ノルディスク アクティーゼルスカブ 電子制御される注射器即ち注入装置
PT1360202E (pt) 2001-02-16 2008-09-01 Conjuchem Biotechnologies Inc Peptídeo do tipo glucagon 2 (glp-2) de longa duração para o tratamento de doenças e distúrbios gastrointestinais
EP1949908A1 (en) 2001-03-07 2008-07-30 Novo Nordisk A/S Combined use of derivatives of GLP-1 analogs and PPAR ligands
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
ES2400057T3 (es) 2001-05-16 2013-04-05 Eli Lilly And Company Aparato inyector de medicamentos
EP1391209A4 (en) 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
GB0113881D0 (en) 2001-06-07 2001-08-01 Innovate Biomed Ltd Foil cutting system
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
US6872705B2 (en) 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
DE10163326A1 (de) 2001-07-30 2003-02-27 Disetronic Licensing Ag Verabreichungsgerät mit Dosiervorrichtung
CN1335182A (zh) 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
EP1432430A4 (en) 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
US6676641B2 (en) 2001-09-05 2004-01-13 Futura Medical Technologies, Inc. Retractable hypodermic syringe
MXPA04003553A (es) 2001-10-18 2004-07-22 Bristol Myers Squibb Co Mimeticos del peptido-1 similares aglucagon humano y su uso en tratamiento de diabetes y condiciones relacionadas.
CN1571676A (zh) 2001-10-19 2005-01-26 伊莱利利公司 Glp－1和胰岛素的双相混合物
EP1478233B1 (en) 2002-02-20 2016-11-09 Emisphere Technologies, Inc. Method for administering glp-1 molecules
JP2005527508A (ja) 2002-03-07 2005-09-15 ヴェクトゥラ　リミテッド 経口デリバリー用急速溶融多粒子製剤
ES2271515T3 (es) 2002-03-15 2007-04-16 Natimmune A/S Composiciones farmaceuticas que comprenden lecitina de union a manosa.
JP2005535569A (ja) 2002-04-04 2005-11-24 ノボ・ノルデイスク・エー／エス Ｇｌｐ−１アゴニスト及び心臓血管合併症
JP2005535652A (ja) 2002-07-09 2005-11-24 サンド・アクチエンゲゼルシヤフト １，２−プロピレングリコールを含有するヒト成長ホルモン（ｈＧＨ）の高濃度液体製剤
US6945961B2 (en) 2002-07-10 2005-09-20 Novo Nordisk A/S Injection device
JP2005532129A (ja) 2002-07-10 2005-10-27 ノボ・ノルデイスク・エー／エス 投与量設定リミッタを備える注入器
EP1391794A1 (en) 2002-07-23 2004-02-25 Novo Nordisk A/S Device with time indicating means
EP1539279B1 (en) 2002-08-29 2006-06-28 Novo Nordisk A/S Frontloaded injection device
WO2004028598A1 (en) 2002-09-24 2004-04-08 Shl Medical Ab Injecting device
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
WO2004029076A2 (en) 2002-09-25 2004-04-08 Novo Nordisk A/S Purification process comprising microfiltration at elevated temperatures
AU2003278929A1 (en) 2002-10-18 2004-05-13 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
EP1610811A4 (en) 2002-12-17 2008-03-26 Amylin Pharmaceuticals Inc PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS
WO2004066939A2 (en) 2003-01-27 2004-08-12 Sarnoff Corporation Controlled-release drug delivery system
GB0304823D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
GB0304824D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
GB0304822D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
GB0306642D0 (en) 2003-03-22 2003-04-30 Dca Design Int Ltd Improvements in and relating to an injector for a medical product
GB0308267D0 (en) 2003-04-10 2003-05-14 Dca Design Int Ltd Improvements in and relating to a pen-type injector
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
ATE541582T1 (de) 2003-06-03 2012-02-15 Novo Nordisk As Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
WO2004105781A2 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
KR101121317B1 (ko) 2003-08-12 2012-03-09 일라이 릴리 앤드 캄파니 기계적 확대율을 갖는 삼중 나사식 쓰레드를 갖는 약제투여 장치
US20070275877A1 (en) 2003-08-29 2007-11-29 Amylin Pharmaceuticals, Inc. Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
JP4949838B2 (ja) 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
TW200523252A (en) 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
DK2149585T3 (da) 2003-11-04 2013-10-21 Novartis Vaccines & Diagnostic Anvendelse af antagonistiske anti-CD40-monoklonale antistoffer
EP1725249B1 (en) 2003-11-06 2014-01-08 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
WO2005046716A1 (en) 2003-11-13 2005-05-26 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia
HUE043210T2 (hu) 2003-11-20 2019-08-28 Novo Nordisk As Injekciós eszközök elõállítására optimális propilénglikol-tartalmú peptidkészítmények
WO2005058252A2 (en) 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Glp-1 pharmaceutical compositions
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
JP2008500281A (ja) 2004-02-11 2008-01-10 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリンファミリーペプチドおよびそれらを作成し使用するための方法
WO2005113008A1 (en) 2004-05-21 2005-12-01 Mediplex Corp. Delivery agents for enhancing mucosal absorption of therapeutic agents
US7448385B2 (en) 2004-06-07 2008-11-11 Purepharm Inc. Nasal adaptation of an oral inhaler device
CN1950078A (zh) 2004-06-11 2007-04-18 诺和诺德公司 使用glp－1激动剂抵抗药物诱发的肥胖
US20090042781A1 (en) 2004-06-28 2009-02-12 Novo Nordisk A/S Methods for Treating Diabetes
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
CA2584806C (en) 2004-11-01 2014-06-17 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
WO2007055728A1 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
US20090011976A1 (en) 2004-11-12 2009-01-08 Novo Nordisk A/S Stable Formulations Of Peptides
CN112618700A (zh) 2004-11-12 2021-04-09 诺和诺德公司 促胰岛素肽的稳定制剂
JP5324098B2 (ja) 2004-11-16 2013-10-23 アルケルメス ファーマ アイルランド リミテッド 注射可能なナノ粒子のオランザピン製剤
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
RU2401133C2 (ru) 2005-01-21 2010-10-10 Ново Нордиск А/С Автоматическое инъекционное устройство с верхним разблокирующим механизмом
AU2006214443C1 (en) 2005-02-15 2011-11-24 Alkermes Pharma Ireland Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
CA2600836A1 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2007014051A2 (en) 2005-07-22 2007-02-01 Amylin Pharmaceuticals, Inc. Use of amylin and amylin agonists as cardioprotective or myoprotective agents
WO2007022518A2 (en) 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
EP1978926A2 (en) 2005-12-19 2008-10-15 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses thereof
US20080181910A1 (en) 2005-12-29 2008-07-31 Boehringer Ingelheim Vetmedica, Inc. Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
BRPI0710651A2 (pt) 2006-04-13 2011-08-23 Sod Conseils Rech Applic composições farmacêuticas de hglp-1, expedina-4 e seus análogos e uso das mesmas
TW200821386A (en) 2006-07-18 2008-05-16 Centocor Inc Human GLP-1 mimetibodies, compositions, methods and uses
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
UY30820A1 (es) 2006-12-21 2008-07-03 Centocor Inc Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
GB0704846D0 (en) 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
PL2157967T3 (pl) 2007-04-23 2013-06-28 Intarcia Therapeutics Inc Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
US20080293814A1 (en) 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
CN101842109B (zh) 2007-09-05 2014-01-29 诺沃-诺迪斯克有限公司 用a-b-c-d-衍生的肽和它们的治疗用途
WO2009033797A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a petide as a therapeutic agent
WO2009051992A1 (en) 2007-10-19 2009-04-23 Bausch & Lomb Incorporated Compositions and methods for treating diseases involving ocular angiogenesis by inhibiting one or more selected receptor tyrosine kinases
JP2011503180A (ja) 2007-11-14 2011-01-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 肥満ならびに肥満関連の疾患および障害の処置方法
EP2231191A2 (en) 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
EP2340261B1 (en) 2008-10-21 2017-12-20 Novo Nordisk A/S Amylin derivatives
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
EP2437816B1 (en) 2009-06-04 2013-04-24 Novo Nordisk Health Care AG Mixing device with piston coupling arrangement
DK2459171T3 (en) 2009-07-31 2017-09-25 Sanofi Aventis Deutschland Long-acting insulin composition
EP2459228B1 (en) 2009-07-31 2020-03-04 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an insulin linker conjugate
WO2011050008A2 (en) 2009-10-19 2011-04-28 Amylin Pharmaceuticals, Inc. Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders
ES2742263T3 (es) 2009-12-10 2020-02-13 Merck Patent Gmbh Composiciones farmacéuticas que comprenden oligopéptidos, preferiblemente cilengitida
TWI484974B (zh) 2009-12-16 2015-05-21 Novo Nordisk As 雙重醯化ｇｌｐ－１衍生物
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
WO2011109784A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Formulation of insulinotropic peptide conjugates
BR112012024379A2 (pt) 2010-03-26 2017-01-10 Novo Nordisk As "peptídeos glucagon, seu uso, bem como composição farmacêutica"
US9217022B2 (en) 2010-07-28 2015-12-22 Astrazeneca Pharmaceuticals Lp GLP-1 receptor agonist compounds having stabilized regions
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
WO2012062803A1 (en) 2010-11-09 2012-05-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2012089445A1 (en) 2010-12-06 2012-07-05 Novo Nordisk Health Care Ag Wheel operated drug delivery device
SG192621A1 (en) 2011-02-04 2013-09-30 Biocopea Ltd Compositions and methods for treating cardiovascular diseases
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
RU2669999C2 (ru) 2011-06-10 2018-10-17 Ново Нордиск А/С Полипептиды
WO2013009539A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
CA2841964A1 (en) 2011-07-20 2013-01-24 Hospira, Inc. Methods of treating pain
US9132170B2 (en) 2011-07-29 2015-09-15 Case Western Reserve University Compositions and methods for treating cognitive deficits
WO2013037690A1 (en) 2011-09-06 2013-03-21 Novo Nordisk A/S Glp-1 derivatives
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
CN104244981A (zh) 2011-12-09 2014-12-24 诺和诺德A/S Glp-1激动剂
EP2820038B1 (en) 2012-03-01 2020-06-17 Novo Nordisk A/S Glp-1 prodrugs
CN102579350B (zh) 2012-03-02 2013-04-24 海南灵康制药有限公司 右旋布洛芬脂质体固体制剂
HK1207306A1 (en) 2012-04-02 2016-01-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
EP2841089A4 (en) 2012-04-03 2016-03-16 Univ Boston COMPOSITIONS, PROCESSES AND ASSAYS WITH AMYLIN OR AMLYANANALOGA FOR ABETA PEPTIDE-MEDIATED ILLNESSES
WO2013156594A1 (en) 2012-04-19 2013-10-24 Novo Nordisk A/S Human amylin analogues
US11274135B2 (en) 2012-05-08 2022-03-15 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US10000542B2 (en) 2012-05-08 2018-06-19 Novo Nordisk A/S Double-acylated GLP-1 derivatives
WO2013177565A1 (en) 2012-05-25 2013-11-28 Amylin Pharmaceuticals, Llc Insulin-pramlintide compositions and methods for making and using them
KR101720885B1 (ko) 2012-06-19 2017-03-28 데비오팜 인터네셔날 에스 에이 (e)-n-메틸-n-((3-메틸벤조푸란-2-일)메틸)-3-(7-옥소-5,6,7,8-테트라히드로-1,8-나프티리딘-3-일)아크릴아미드의전구약물 유도체
RS60432B1 (sr) 2012-07-01 2020-07-31 Novo Nordisk As Upotreba glp-1 peptida sa dugim dejstvom
EP2908844A1 (en) 2012-10-17 2015-08-26 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
US20140187635A1 (en) 2012-12-28 2014-07-03 Themis Medicare Limited Diclofenac compositions
EP2970389B1 (en) 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
JP2014214153A (ja) * 2013-04-30 2014-11-17 ニプロ株式会社 水溶液製剤およびその製造方法
ES2688462T3 (es) 2013-05-02 2018-11-02 Novo Nordisk A/S Dosificación oral de compuestos de GLP-1
BR112015028173A2 (pt) 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
US20160136246A1 (en) 2013-06-21 2016-05-19 Novo Nordisk A/S Novel Uses of GLP-1 Receptor Agonists in Patients Treated with Insulin and/or Suffering from Type 1 Diabetes
AU2014286234A1 (en) 2013-07-04 2015-12-17 Novo Nordisk A/S Derivatives of GLP-1 like peptides, and uses thereof
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CN103405753B (zh) 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
EP3129041B1 (en) 2014-04-07 2019-06-12 Novo Nordisk A/S Double-acylated glp-1 compounds
KR20170021313A (ko) 2014-06-25 2017-02-27 글락소스미스클라인 엘엘씨 제약 조성물
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
WO2016038521A1 (en) 2014-09-08 2016-03-17 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of liraglutide
CN105777872B (zh) 2014-12-16 2019-06-07 深圳翰宇药业股份有限公司 一种萨摩鲁肽的纯化方法
CN107249620B (zh) 2015-05-13 2018-06-26 杭州九源基因工程有限公司 一种包含glp-1类似物的药物制剂及其制备方法
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US20170071970A1 (en) * 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
US11383036B2 (en) 2015-12-30 2022-07-12 Novo Nordisk A/S Mechanism for sequential dose delivery
JP7053480B2 (ja) 2016-03-03 2022-04-12 ノヴォ ノルディスク アー／エス Ｇｌｐ－１誘導体及びその使用
PL3448416T3 (pl) * 2016-04-28 2022-11-07 Novo Nordisk A/S Semaglutyd w schorzeniach sercowo-naczyniowych
JP2019535835A (ja) 2016-11-22 2019-12-12 バイオコン リサーチ リミテッドＢｉｏｃｏｎ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ Ｇｌｐ−１類似体の医薬組成物
GB201621987D0 (en) 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
KR20190124704A (ko) 2017-01-24 2019-11-05 마크레젠, 인크. 아포지질단백질 모방체를 이용하는, 나이 관련 황반 변성 및 기타 안질환의 치료
AR110988A1 (es) * 2017-02-21 2019-05-22 Sanofi Sa Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados
MA46990B1 (fr) 2017-08-24 2024-03-29 Novo Nordisk As Compositions glp-1 et ses utilisations
KR20200069316A (ko) * 2017-10-12 2020-06-16 노보 노르디스크 에이/에스 의료 요법에서의 세마글루타이드
US11590206B2 (en) * 2017-12-21 2023-02-28 Sanofi Liquid pharmaceutical composition
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
JP2020002130A (ja) 2018-06-25 2020-01-09 Ｊｃｒファーマ株式会社 蛋白質含有水性液剤
RS64438B1 (sr) * 2018-10-26 2023-09-29 Novo Nordisk As Stabilne kompozicije semaglutida i njihova upotreba
JP2023512910A (ja) * 2020-02-18 2023-03-30 ノヴォ ノルディスク アー／エス 医薬製剤

Also Published As

Publication number Publication date
AU2021208601A1 (en) 2022-07-28
US11318191B2 (en) 2022-05-03
US20230082544A1 (en) 2023-03-16
PE20221575A1 (es) 2022-10-06
CL2022002084A1 (es) 2023-01-13
US20210252111A1 (en) 2021-08-19
JP2023512910A (ja) 2023-03-30
EP4537848A3 (en) 2025-06-25
EP4537848A2 (en) 2025-04-16
EP4106727A1 (en) 2022-12-28
JP2022513346A (ja) 2022-02-07
PE20230819A1 (es) 2023-05-19
IL294520A (en) 2022-09-01
CN115135305A (zh) 2022-09-30
JP2022125213A (ja) 2022-08-26
EP4106724A1 (en) 2022-12-28
US20250152673A1 (en) 2025-05-15
BR112022013746A2 (pt) 2022-10-11
BR112022013795A2 (pt) 2022-09-13
WO2021144476A1 (en) 2021-07-22
CO2022011728A2 (es) 2022-10-31
JP7132441B2 (ja) 2022-09-06
WO2021144477A1 (en) 2021-07-22
KR20220143037A (ko) 2022-10-24
MX2022009523A (es) 2022-09-09
TWI878456B (zh) 2025-04-01
KR20220143036A (ko) 2022-10-24
CN115135304A (zh) 2022-09-30
TW202140062A (zh) 2021-11-01
AU2021207313A1 (en) 2022-07-28
CA3165355A1 (en) 2021-07-22
CO2022010915A2 (es) 2022-11-08
AU2021208601B2 (en) 2025-06-05
CA3165359A1 (en) 2021-07-22
TW202140063A (zh) 2021-11-01
US20230093542A1 (en) 2023-03-23
IL294521A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
MX2022009844A (es) Composiciones y usos del peptido similar al glucagon-1 (glp-1).
EP4360651A3 (en) Glp-1 compositions and uses thereof
WO2021262826A3 (en) 1'-cyano nucleoside analogs and uses thereof
RS20050066A (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
EA025267B1 (ru) Водная фармацевтическая композиция этанерцепта, стабилизированная глутаматом
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
DE60110054D1 (en) Cardioprotektive phosphonate
MX2024014480A (es) Composiciones farmaceuticas acuosas que comprenden inhibidores de sglt-2
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
MX2021001272A (es) Composiciones de bismuto-tiol y metodos de uso.
MX2024001417A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington.
CN117157299A8 (zh) 三环杂环衍生物及其组合物和应用
EP4400098A3 (en) Co-amorphous forms of beta-lactoglobulin and a drug substance
AU2002303856A1 (en) Gpe analogs and peptidomimetics
MX2023006281A (es) Composicion farmaceutica de agonistas duales de glp-1/glp-2.
MX2023006280A (es) Composicion farmaceutica de agonistas duales de glp-1/glp-2.
MX2025002929A (es) Compuestos de objetivo brm y metodos de uso asociados
MX2024014216A (es) Compuestos aromaticos que contienen boro y analogos de insulina relacionados
MX2024001093A (es) Composiciones que comprenden un constituyente, derivado o extracto de cannabis.
BR0315620A (pt) Derivados de n-benzodioxolil, n-benzodioxanil e n-benzodioxepinil arilcarboxamida, e composições farmacêuticas compreendendo os mesmos
MX2022007175A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
WO2020260956A3 (en) Self-emulsifying cannabidiol formulations